Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranibizumab + levosulpiride
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Ophthalmic, Oral, Intramuscular
01
Overview
This is a combination therapy consisting of ranibizumab and levosulpiride. Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment that targets vascular endothelial growth factor A (VEGF-A), used to treat various ocular disorders including diabetic macular edema and age-related macular degeneration. Levosulpiride is a selective dopamine D2 receptor antagonist and serotonin 5-HT4 receptor agonist used for psychiatric conditions, depression, and gastrointestinal disorders. The combination is being investigated for potential synergistic effects in treating retinal conditions.
02
Targets
DRD2 (Dopamine D2 Receptor)HTR4 (5-Hydroxytryptamine receptor 4)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ranibizumab + levosulpiride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranibizumab + levosulpiride.